3 suspended. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Suspended 3 |
| Phase 1 | 1 | Suspended 1 |
Follow Heredodegenerative Disorders, Nervous System: new trials by email Literature Review of Heredodegenerative Disorders, Nervous System trials Research Report on Heredodegenerative Disorders, Nervous System
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome Psilocybin, 1.5 mg - Fragile X Syndrome, Behavior | Phase 2 | Suspended | Nova Mentis Life Science Corp | 10 | 2023-03-28 | 2024-05-08 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome STX107 - Fragile X Syndrome | Phase 2 | Suspended | Seaside Therapeutics, Inc. | 16 | 2011-05-01 | 2012-12-20 |
Fragile X Syndrome (2) · Behavior (1) · Cognitive Dysfunction (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neurobehavioral Manifestations (1) · Recurrence (1)
Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Nervous System Diseases (3) · Chromosome Disorders (2) · Genetic Diseases, X-Linked (2) · Intellectual Disability (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Sex Chromosome Disorders (2) · X-Linked Intellectual Disability (2) · Bone Marrow Diseases (1) · Cognition Disorders (1) · Disease Attributes (1)
CA-4948 (1) · Psilocybin (1) · venetoclax (1)
Curis, Inc. (1) · Nova Mentis Life Science Corp (1) · Seaside Therapeutics, Inc. (1)
United States (2) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1)
David Crowley, MD (1) · Marvin Hausman, MD (1)